Optimal first-line treatment of chronic myeloid leukemia: How to use imatinib and what role for newer drugs?

ONCOLOGY

Volumn 21, Issue 6, 2007, Pages 653-662

  Jabbour, Elias ^a   Cortes, Jorge ^a   Kantarjian, Hagop ^a  

^a UNIVERSITY OF TEXAS   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIDIARRHEAL AGENT; ANTIEMETIC AGENT; ANTIINFLAMMATORY AGENT; ANTINEOPLASTIC AGENT; BCR ABL PROTEIN; BOSUTINIB; CALCIUM; DASATINIB; DIURETIC AGENT; IMATINIB; INNO 406; NILOTINIB; NOVEL ERYTHROPOIESIS STIMULATING PROTEIN; NS 187; QUININE; RECOMBINANT ERYTHROPOIETIN; RECOMBINANT GRANULOCYTE COLONY STIMULATING FACTOR; RECOMBINANT INTERLEUKIN 11; STEROID; UNCLASSIFIED DRUG;

ANEMIA; ASCITES; BLEEDING; BONE MARROW SUPPRESSION; BONE PAIN; CANCER IMMUNOTHERAPY; CANCER REGRESSION; CARDIOTOXICITY; CHROMOSOME ABERRATION; CHRONIC MYELOID LEUKEMIA; CLINICAL TRIAL; CONGESTIVE HEART FAILURE; CYTOGENETICS; DIARRHEA; DRUG MEGADOSE; DRUG USE; DRUG WITHDRAWAL; EDEMA; FLUID RETENTION; GENE MUTATION; HUMAN; LIVER DYSFUNCTION; LIVER FUNCTION; LIVER TOXICITY; LUNG EDEMA; MINIMAL RESIDUAL DISEASE; MONOSOMY 7; MUSCLE CRAMP; MUSCULOSKELETAL PAIN; NAUSEA; NEUTROPENIA; PLEURA EFFUSION; RASH; REVIEW; SIDE EFFECT; STEM CELL TRANSPLANTATION; THROMBOCYTOPENIA; TREATMENT DURATION; TRISOMY 8; VOMITING; WEIGHT GAIN;

ANTINEOPLASTIC AGENTS; CHROMOSOME ABERRATIONS; CLINICAL TRIALS; DRUG ADMINISTRATION SCHEDULE; DRUG MONITORING; DRUG RESISTANCE, NEOPLASM; HUMANS; LEUKEMIA, MYELOID, CHRONIC; PIPERAZINES; PROTEIN-TYROSINE KINASES; PYRIMIDINES; SURVIVAL ANALYSIS;

EID: 34249940036     PISSN: 08909091     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (119)

1. Jemal A, Siegel R, Ward E, et al: Cancer statistics, 2006. CA Cancer J Clin 56:106-130, 2006.
2. Faderl S, Talpaz M, Estrov Z, et al: The biology of chronic myeloid leukemia. N Engl J Med 341:164-172, 1999.
3. Goldman JM, Melo JV: Chronic myeloid leukemia - advances in biology and new approaches to treatment. N Engl J Med 349:1451-1464, 2003.
4. Barnes DJ, Melo JV: Cytogenetic and molecular genetic aspects of chronic myeloid leukaemia. Acta Haematol 108:180-202, 2002.
5. Rowley JD: A new consistent chromosomal abnormality in chronic myelogenous leukaemia identified by quinacrine fluorescence and Giemsa staining. Nature 243:290-293, 1973.
6. Thomas ED, Clift RA, Fefer A, et al: Marrow transplantation for the treatment of chronic myelogenous leukemia. Ann Intern Med 104:155-163, 1986.
7. Kantarjian HM, O'Brien S, Cortes J, et al: Complete cytogenetic and molecular responses to interferon-alpha-based therapy for chronic myelogenous leukemia are associated with excellent long-term prognosis. Cancer 97:1033-1041, 2003.
8. Kantarjian H, Sawyers C, Hochhaus A, et al: Hematologic and cytogenetic responses to imatinib mesylate in chronic myelogenous leukemia. N Engl J Med 346:645-652, 2002.
9. Kantarjian HM, Cortes JE, O'Brien S, et al: Long-term survival benefit and improved complete cytogenetic and molecular response rates with imatinib mesylate in Philadelphia chromosome-positive chronic-phase chronic myeloid leukemia after failure of interferon-{alpha}. Blood 104:1979-1988, 2004.
10. O'Brien SG, Guilhot F, Larson RA, et al: Imatinib compared with interferon and low-dose cytarabine for newly diagnosed chronic-phase chronic myeloid leukemia. N Engl J Med 348:994-1004, 2003.
11. Kantarjian H, Talpaz M, O'Brien S, et al: High-dose imatinib mesylate therapy in newly diagnosed Philadelphia chromosome-positive chronic phase chronic myeloid leukemia. Blood 103:2873-2878, 2004.
12. Cortes J, Talpaz M, O'Brien S, et al: Molecular responses in patients with chronic myelogenous leukemia in chronic phase treated with imatinib mesylate. Clin Cancer Res 11:3425-3432, 2005.
13. Hughes TP, Kaeda J, Branford S, et al: Frequency of major molecular responses to imatinib or interferon alfa plus cytarabine in newly diagnosed chronic myeloid leukemia. N Engl J Med 349:1423-1432, 2003.
14. Druker BJ, Tamura S, Buchdunger E, et al: Effects of a selective inhibitor of the Abl tyrosine kinase on the growth of Bcr-Abl positive cells. Nat Med 2:561-566, 1996.
15. Beran M, Cao X, Estrov Z, et al: Selective inhibition of cell proliferation and BCR-ABL phosphorylation in acute lymphoblastic leukemia cells expressing Mr 190,000 BCR-ABL protein by a tyrosine kinase inhibitor (CGP-57148). Clin Cancer Res 4:1661-1672, 1998.
16. Buchdunger E, Zimmermann J, Mett H, et al: Inhibition of the Abl protein-tyrosine kinase in vitro and in vivo by a 2-phenylaminopyrimidine derivative. Cancer Res 56:100-104, 1996.
17. Buchdunger E, Cioffi CL, Law N, et al: Abl protein-tyrosine kinase inhibitor STI571 inhibits in vitro signal transduction mediated by c-kit and platelet-derived growth factor receptors. J Pharmacol Exp Ther 295:139-145, 2000.
18. Okuda K, Weisberg E, Gilliland DG, et al: ARG tyrosine kinase activity is inhibited by STI571. Blood 97:2440-2448, 2001.
19. Heinrich MC, Blanke CD, Druker BJ, et al: Inhibition of KIT tyrosine kinase activity: a novel molecular approach to the treatment of KIT-positive malignancies. J Clin Oncol 20:1692-1703, 2002.
20. Dewar AL, Cambareri AC, Zannettino AC, et al: Macrophage colony stimulating factor receptor, c-fms, is a novel target of imatinib. Blood 105:3127-3132, 2005.
21. Ren R: Mechanisms of BCR-ABL in the pathogenesis of chronic myelogenous leukaemia. Nat Rev Cancer 5:172-183, 2005.
22. O'Brien SG, Guilhot F, Larson RA, et al: Imatinib compared with interferon and low-dose cytarabine for newly diagnosed chronic-phase chronic myeloid leukemia. N Engl J Med 348:994-1004, 2003.
23. Druker BJ, Guilhot F, O'Brien S, et al: Five-year follow-up of patients receiving imatinib for chronic myeloid leukemia. N Engl J Med 355:2408-2417, 2006.
24. Kantarjian HM, O'Brien S, Cortes J, et al: Imatinib mesylate therapy improves survival in patients with newly diagnosed Philadelphia chromosome-positive chronic myelogenous leukemia in the chronic phase. Comparison with historic data. Cancer 98:2636-2642, 2003.
25. Kantarjian HM, Talpaz M, O'Brien S, et al: Survival benefit with imatinib mesylate versus interferon alpha-based regimens in newly diagnosed chronic phase chronic myelogenous leukemia. Blood 108:1835-1840, 2006.
26. Roy L, Guilhot J, Kranhke T, et al: Survival advantage from imatinib compared to the combination interferon-{alpha} plus cytarabine in chronic phase CML: Historical comparison between two phase III trials. Blood 108:1478-1484, 2006.
27. Talpaz M, Silver RT, Druker BJ, et al: Imatinib induces durable hematologic and cytogenetic responses in patients with accelerated phase chronic myeloid leukemia: Results of a phase 2 study. Blood 99:1928-1937, 2002.
28. Sawyers CL, Hochhaus A, Feldman E, et al: Imatinib induces hematologic and cytogenetic responses in patients with chronic myelogenous leukemia in myeloid blast crisis: Results of a phase 11 study. Blood 99:3530-3539, 2002.
29. Kerkela R, Grazette L, Yacobi R, et al: Cardiotoxicity of the cancer therapeutic agent imatinib mesylate. Nat Med 12:908-916, 2006.
30. Atallah E, Durand JB, Kantarjian H, et al: Congestive heart failure is a rare event in patients receiving imatinib therapy (abstract 246). Blood 108:2006.
31. Deininger MW, O'Brien SG, Ford JM, et al: Practical management of patients with chronic myeloid leukemia receiving imatinib. J Clin Oncol 21:1637-1647, 2003.
32. Quintas-Cardama A, Kantarjian H, O'Brien S, et al: Granulocyte-colony- stimulating factor (filgrastim) may overcome imatinib-induced neutropenia in patients with chronic-phase chronic myelogenous leukemia. Cancer 100:2592-2597, 2004.
33. Mauro MJ, Kurilik G, Balleisen S, et al: Myeloid growth factors for neutropenia during imatinib mesylate therapy for CML: Preliminary evidence of safety and efficacy (abstract). Blood 98:139a, 2001.
34. Marin D, Marktel S, Foot N, et al: G-CSF reverses cytopenia and may increase cytogenetic responses in patients with CML treated with imatinib mesylate (abstract). Blood 100:782a, 2002.
35. Ault P, Kantarjian H, Welch MA, et al: Interleukin 11 may improve thrombocytopenia associated with imatinib mesylate therapy in chronic myelogenous leukemia. Leuk Res 28:613-618, 2004.
36. Cortes J, O'Brien S, Quintas A, et al: Erythropoietin is effective in improving the anemia induced by imatinib mesylate therapy in patients with chronic myeloid leukemia in chronic phase. Cancer 100:2396-2402, 2004.
37. Mauro MJ, Blasdel C, O'Dwyer ME, et al: Erythropoietin for anemia during imatinib mesylate (STI571) therapy for CML: Preliminary evidence of safety and efficacy (abstract 106). Proc Am Soc Clin Oncol 21:27a, 2002.
38. Ault P, Kantarjian H, O'Brien S, et al: Use of darbepoetin alfa for the treatment of anemia occurring during imatinib therapy for CML: Preliminary evidence of safety and efficacy (abstract 2467). Proc Am Soc Clin Oncol 22:613, 2003.
39. Peng B, Hayes M, Resta D, et al: Pharmacokinetics and pharmacodynamics of imatinib in a phase I trial with chronic myeloid leukemia patients. J Clin Oncol 22:935-942, 2004.
40. Schmidli H, Peng B, Riviere GJ, et al: Population pharmacokinetics of imatinib mesylate in patients with chronic-phase chronic myeloid leukaemia: Results of a phase III study. Br J Clin Pharmacol 60:35-44, 2005.
41. Cortes J, Giles F, O'Brien S, et al: Result of high-dose imatinib mesylate in patients with Philadelphia chromosome-positive chronic myeloid leukemia after failure of interferon-á. Blood 102:83-86, 2003.
42. Kantarjian H, Talpaz M, O'Brien S, et al: Dose escalation of imatinib mesylate can overcome resistance to standard-dose therapy in patients with chronic myelogenous leukemia. Blood 101:473-475, 2003.
43. Hughes TP, Branford S, Matthews J, et al: Trial of higher dose imatinib with selective intensification in newly diagnosed CML patients in chronic phase (abstract 95). Blood 102:31a, 2003.
44. Cortes J, Giles F, Salvado A, et al: High-dose (HD) imatinib in patients with previously untreated chronic myeloid leukemia (CML) in early chronic phase (CP): Preliminary results of a multicenter community based trial (abstract 6518). J Clin Oncol 23(16S):564s, 2005.
45. Rosti G, Martinelli G, Castagnetti F, et al: Imatinib 800 mg: preliminary results of a phase II trial of the GIMEMA CML working party in intermediate sokal risk patients and status-of-the-art of an ongoing multinational, prospective randomized trial of imatinib standard dose (400 mg daily) s high dose (800 mg daily) in high Sokal risk patients (abstract 1098). Blood 106:320a, 2005.
46. Aoki E, Kantarjian H, O'Brien S, et al: High-dose (HD) imatinib provides better responses in patients with untreated early chronic phase (CP) chronic myeloid leukemia (CML) (abstract 2143). Blood 108:2006.
47. Hughes TP, Deininger MW, Hochhaus A, et al: Monitoring CML patients responding to treatment with tyrosine kinase inhibitors: review and recommendations for harmonizing current methodology for detecting BCR-ABL transcripts and kinase domain mutations and for expressing results. Blood 108:28-37, 2006.
48. Bumm T, Muller C, Al-Ali HK, et al: Emergence of clonal cytogenetic abnormalities in Ph- cells in some CML patients in cytogenetic remission to imatinib but restoration of polyclonal hematopoiesis in the majority. Blood 101:1941-1949, 2003.
49. Feldman E, Najfeld V, Schuster M, et al: The emergence of Ph-, trisomy -8+ cells in patients with chronic myeloid leukemia treated with imatinib mesylate. Exp Hematol 31:702-707, 2003.
50. Marktel S, Marin D, Foot N, et al: Chronic myeloid leukemia in chronic phase responding to imatinib: The occurrence of additional cytogenetic abnormalities predicts disease progression. Haematologica 88:260-267, 2003.
51. Medina J, Kantarjian H, Talpaz M, et al: Chromosomal abnormalities in Philadelphia chromosome-negative metaphases appearing during imatinib mesylate therapy in patients with Philadelphia chromosome-positive chronic myelogenous leukemia in chronic phase. Cancer 98:1905-1911, 2003.
52. Terre C, Eclache V, Rousselot P, et al: Report of 34 patients with clonal chromosomal abnormalities in Philadelphia-negative cells during imatinib treatment of Philadelphia-positive chronic myeloid leukemia. Leukemia 18:1340-1346, 2004.
53. Jabbour E, Kantarjian H, O'Brien S, et al: Chromosomal abnormalities in Philadelphia chromosome (Ph)-negative metaphases appearing during imatinib mesylate (IM) therapy in patients (pts) with newly diagnosed chronic myeloid leukemia (CML) in chronic phase (abstract 1090). Blood 106:317a, 2005.
54. Lin Y, Bruyere H, Horsman DE, et al: Philadelphia-negative clonal hematopoiesis following imatinib therapy in patients with chronic myeloid leukemia: A report of nine cases and analysis of predictive factors. Cancer Genet Cytogenet 170:16-23, 2006.
55. Fayad L, Kantarjian H, O'Brien S, et al: Emergence of new clonal abnormalities following interferon-alpha induced complete cytogenetic response in patients with chronic myeloid leukemia: Report of three cases. Leukemia 11:767-771, 1997.
56. Izumi T, Imagawa S, Hatake K, et al: Philadelphia chromosome-negative cells with trisomy 8 after busulfan and interferon treatment of Ph1-positive chronic myelogenous leukemia. Int J Hematol 64:73-77, 1996.
57. Fabarius A, Giehl M, Frank O, et al: Induction of centrosome and chromosome aberrations by imatinib in vitro. Leukemia 19:1573-1578, 2005.
58. Gorre ME, Mohammed M, Ellwood K, et al: Clinical resistance to STI-571 cancer therapy caused by BCR-ABL gene mutation or amplification. Science 293:876-880, 2001.
59. Hochhaus A, Kreil S, Corbin AS, et al: Molecular and chromosomal mechanisms of resistance to imatinib (STI571) therapy. Leukemia 16:2190-2196, 2002.
60. Illmer T, Schaich M, Platzbecker U, et al: P-glycoprotein-mediated drug efflux is a resistance mechanism of chronic myelogenous leukemia cells to treatment with imatinib mesylate. Leukemia 18:401-408, 2004.
61. Thomas J, Wang L, Clark RE, et al: Active transport of imatinib into and out of cells: Implications for drug resistance. Blood 104:3739-3745, 2004.
62. Larghero J, Leguay T, Mourah S, et al: Relationship between elevated levels of the alpha 1 acid glycoprotein in chronic myelogenous leukemia in blast crisis and pharmacological resistance to imatinib (Gleevec) in vitro and in vivo. Biochem Pharmacol 66:1907-1913, 2003.
63. le Coutre P, Kreuzer KA, Na IK, et al: Determination of alpha-1 acid glycoprotein in patients with Ph+ chronic myeloid leukemia during the first 13 weeks of therapy with STI571. Blood Cells Mol Dis 28:75-85, 2002.
64. Lionberger JM, Wilson MB, Smithgall TE: Transformation of myeloid leukemia cells to cytokine independence by Bcr-Abl is suppressed by kinase-defective Hck. J Biol Chem 275:18581-18585, 2000.
65. Donato NJ, Wu JY, Stapley J, et al: BCR-ABL independence and LYN kinase overexpression in chronic myelogenous leukemia cells selected for resistance to STI571. Blood 101:690-698, 2003.
66. Dai Y, Rahmani M, Corey SJ, et al: A Bcr/Abl-independent, Lyn-dependent form of imatinib mesylate (STI-571) resistance is associated with altered expression of Bcl-2. J Biol Chem 279:34227-34239, 2004.
67. Lahaye T, Riehm B, Berger U, et al: Response and resistance in 300 patients with BCR-ABL-positive leukemias treated with imatinib in a single center: A 4.5-year follow-up. Cancer 103:1659-1669, 2005.
68. Deininger M, Buchdunger E, Druker BJ: The development of imatinib as a therapeutic agent for chronic myeloid leukemia. Blood 105:2640-2653, 2005.
69. Litzow MR: Imatinib resistance: Obstacles and opportunities. Arch Pathol Lab Med 130:669-679, 2006.
70. Corbin AS, Buchdunger E, Pascal F, et al: Analysis of the structural basis of specific-ity of inhibition of the Abl kinase by STI571. J Biol Chem 277:32214-32219, 2002.
71. Corbin AS, La RP, Stoffregen EP, et al: Several Bcr-Abl kinase domain mutants associated with imatinib mesylate resistance remain sensitive to imatinib. Blood 101:4611-4614, 2003.
72. Azam M, Latek RR, Daley GQ: Mechanisms of autoinhibition and STI-571/imatinib resistance revealed by mutagenesis of BCR-ABL. Cell 112:831-843, 2003.
73. Shah NP, Nicoll JM, Nagar B, et al: Multiple BCR-ABL kinase domain mutations confer polyclonal resistance to the tyrosine kinase inhibitor imatinib (STI571) in chronic phase and blast crisis chronic myeloid leukemia. Cancer Cell 2:117-125, 2002.
74. von Bubnoff N, Schneller F, Peschel C, et al: BCR-ABL gene mutations in relation to clinical resistance of Philadelphia-chromosome-positive leukaemia to STI571: A prospective study. Lancet 359:487-491, 2002.
75. Branford S, Rudzki Z, Walsh S, et al: Detection of BCR-ABL mutations in patients with CML treated with imatinib is virtually always accompanied by clinical resistance, and mutations in the ATP phosphate-binding loop (P-loop) are associated with a poor prognosis. Blood 102:276-283, 2003.
76. Jabbour E, Kantarjian H, Jones D, et al: Frequency and clinical significance of BCR-ABL mutations in patients with chronic myeloid leukemia treated with imatinib mesylate. Leukemia 20:1767-1773, 2006.
77. Soverini S, Martinelli G, Rosti G, et al: ABL mutations in late chronic phase chronic myeloid leukemia patients with up-front cytogenetic resistance to imatinib are associated with a greater likelihood of progression to blast crisis and shorter survival: A study by the GIMEMA Working Party on Chronic Myeloid Leukemia. J Clin Oncol 23:4100-4109, 2005.
78. Nicolini FE, Corm S, Le QH, et al: Mutation status and clinical outcome of 89 imatinib mesylate-resistant chronic myelogenous leukemia patients: A retrospective analysis from the French intergroup of CML (Fi(varphi)-LMC GROUP). Leukemia 20:1061-1066, 2006.
79. Branford S, Rudzki Z, Parkinson I, et al: Real-time quantitative PCR analysis can be used as a primary screen to identify patients with CML treated with imatinib who have BCR-ABL kinase domain mutations. Blood 104:2926-2932, 2004.
80. Cortes J, O'Brien S, Kantarjian H: Discontinuation of imatinib therapy after achieving a molecular response. Blood 104:2204-2205, 2004.
81. Mauro MJ, Druker BJ, Maziarz RT: Divergent clinical outcome in two CML patients who discontinued imatinib therapy after achieving a molecular remission. Leukemia Res 28:71-73, 2004.
82. Ghanima W, Kahrs J, Dahl TG 3rd, et al: Sustained cytogenetic response after discontinuation of imatinib mesylate in a patient with chronic myeloid leukaemia. Eur J Haematol 72:441-443, 2004.
83. Rousselot P, Huguet F, Rea D, et al: Imatinib mesylate discontinuation in patients with chronic myelogenous leukaemia in complete molecular remission for more than two years. Blood 109:58-60, 2007.
84. Graham SM, Jorgensen HG, Allan E, et al: Primitive quiescent, Philadelphia-positive stem cells from patients with chronic myeloid leukemia are insensitive to STI571 in vitro. Blood. 2002; 99:319-325.
85. Talpaz M, Shah NP, Kantarjian H, et al: Dasatinib in imatinib-resistant Philadelphia chromosome-positive leukemias. N Engl J Med 354:2531-2541, 2006.
86. Cortes JE, Kim DW, Rosti G, et al: Dasatinib (D) in patients (pts) with chronic myelogenous leukemia (CML) in myeloid blast crisis (MBC) who are imatinib-resistant (IM-R) or IM-intolerant (IM-I): Results of the CA180006 'START-B' study (abstract 6529). J Clin Oncol 24(18S):344s, 2006.
87. Coutre S, Martinelli G, Dombret H, et al: Dasatanib (D) in patients (pts) with chronic myelogenous leukemia (CML) in lymphoid blast crisis (LB-CML) or Philadelphia-chromosome positive acute lymphoblastic leukemia (Ph+ALL) who are imatinib (IM)-resistant (IM-R) or intolerant (IM-I): The CA180015 'START-L' study (abstract 6528). J Clin Oncol 24(18S):344s, 2006.
88. Hochhaus A, Kantarjian H, Baccarani M, et al: Dasatinib in patients with chronic phase chronic myeloid leukemia (CP-CML) who are resistant or intolerant to imatinib: Results of the CA180013 'START-C Study (abstract 6508). J Clin Oncol 24(18S):339s, 2006.
89. Shah NP, Rousselot P, Pasquini R, et al: Dasatinib (D) vs high dose imatinib (IM) in patients (pts) with chronic phase chronic myeloid leukemia (CP-CML) resistant to imatinib. Results of CA180017 START-R randomized trial (abstract 6507). J Clin Oncol 24(18S):338s, 2006.
90. Talpaz M, Apperley JF, Kim DW, et al: Dasatinib (D) in patients with accelerated phase chronic myeloid leukemia (AP-CML) who are resistant or intolerant to imatinib: Results of the CA180005 'START-A' study. J Clin Oncol 24(18S):343s, 2006
91. Kantarjian H, Giles F, Wunderle L, et al: Nilotinib in imatinib-resistant CML and Philadelphia chromosome-positive ALL. N Engl J Med 354:2542-2551, 2006.
92. Giles FJ, Larson R, le Coutre P, et al: A phase II study of AMN107, a novel inhibitor of Bcr-Abl, administered to imatinib-resistant or intolerant patients (pts) with Ph+ chronic myelogenous leukemia (CML) in blast crisis (BC) or relapsed/refractory Ph+ acute lymphoblastic leukemia (ALL) (abstract 6536). J Clin Oncol 24(18S):346s, 2006.
93. Kantarjian HM, Gattermann N, O'Brien SG, et al: A phase II study of AMN107, a novel inhibitor of Bcr-Abl, administered to imatinib resistant and intolerant patients (pts) with chronic myelogenous leukemia (CML) in chronic phase (CP) (abstract 6534). J Clin Oncol 24(18S):345s, 2006.
94. Le Coutre PD, Ottmann O, Gatterman N, et al: A phase II study of AMN107, a novel inhibitor of Bcr-Abl, administered to imatinib-resistant or intolerant patients (pts) with chronic myelogenous leukemia (CML) in accelerated phase (AP) (abstract 6531). J Clin Oncol 24(18S):344s, 2006.
95. Jabbour E, Cortes J, Giles F, et al: Preliminary activity of AMN107, a novel potent oral selective Bcr-Abl tyrosine kinase inhibitor, in newly diagnosed Philadelphia chromosome (Ph)-positive chronic phase chronic myelogenous leukaemia (CML-CP) (abstract 2172). Blood 108:2006.
96. Cortes J, O'Brien S, Jones D, et al: Dasatinib in patients with previously untreated chronic myeloid leukemia in chronic phase (abstract 2161). Blood 108:2006.
97. Cortes J, Kantarjian H, Baccarani M, et al: Phase 1/2 study of SKI-606, a dual inhibitor of Src and Abl kinases, in adults patients with Philadelphia chromosome positive (Ph+) chronic myelogenous leukemia (CML) or acute lymphocytic leukemia (ALL) relapsed refractory or intolerant to imatinib (abstract 168). Blood 108:2006.
98. Naito H, Kimura S, Nakaya Y, et al: In vivo antiproliferative effect of NS-187, a dual Bcr-Abl/Lyn tyrosine kinase inhibitor, on leukemic cells harbouring Abl kinase domain mutations. Leuk Res 30:1443-1446, 2006.
99. Grigg A, Hughes T: Role of allogeneic stem cell transplantation for adult chronic myeloid leukemia in the imatinib era. Biol Blood Marrow Transplant 12:795-807, 2006.
100. Jabbour E, Cortes J, Kantarjian, et al: Allogeneic stem cell transplantation for patients with chronic myeloid leukemia and acute lymphocytic leukemia after Bcr-Abl kinase mutation-related imatinib failure. Blood 108:1421-1423, 2006.
101. Radich JP, Gooley T, Bensinger W, et al: HLA-matched related hematopoietic cell transplantation for chronic-phase CML using a targeted busulfan and cyclophosphamide preparative regimen. Blood 102:31-35, 2003.
102. Gratwohl A, Brand R, Apperley J, et al: Allogeneic hematopoietic stem cell transplantation for chronic myeloid leukemia in Europe 2006: Transplant activity, long-term data and current results. An analysis by the Chronic Leukemia Working Party of the European Group for Blood and Marrow Transplantation (EBMT). Haematologica 91:513-521, 2006.
103. Gratwohl A, Hermans J, Goldman JM, et al: Risk assessment for patients with chronic myeloid leukaemia before allogeneic blood or marrow transplantation. Chronic Leukemia Working Party of the European Group for Blood and Marrow Transplantation. Lancet 352:1087-1092, 1998.
104. Kiss TL, Abdolell M, Jamal N, et al: Long-term medical outcomes and quality-of-life assessment of patients with chronic myeloid leukemia followed at least 10 years after allogeneic bone marrow transplantation. J Clin Oncol 20:2334-2343, 2002.
105. Hansen JA, Gooley TA, Martin PJ, et al: Bone marrow transplants from unrelated donors for patients with chronic myeloid leukemia. N Engl J Med 338:962-968, 1998.
106. Weisdorf DJ, Anasetti C, Antin JH, et al: Allogeneic bone marrow transplantation for chronic myelogenous leukemia: Comparative analysis of unrelated versus matched sibling donor transplantation. Blood 99:1971-1977, 2002.
107. Mickelson EM, Petersdorf EW, Hansen JA: HLA matching and hematopoietic cell transplant outcome. Clin Transpl 263-271, 2002.
108. Or R, Shapira MY, Resnick I, et al: Nonmyeloablative allogeneic stem cell transplantation for the treatment of chronic myeloid leukemia in first chronic phase. Blood 101:441-445, 2003.
109. Crawley C, Szydlo R, Lalancette M, et al: Outcomes of reduced-intensity transplantation for chronic myeloid leukemia: An analysis of prognostic factors from the Chronic Leukemia Working Party of the EBMT. Blood 106:2969-2976, 2005.
110. Gilleece MH, Dazzi F: Donor lymphocyte infusions for patients who relapse after allogeneic stem cell transplantation for chronic myeloid leukaemia. Leuk Lymphoma 44:23-28, 2003.
111. Kantarjian HM, O'Brien S, Cortes JE, et al: Imatinib mesylate therapy for relapse after allogeneic stem cell transplantation for chronic myelogenous leukemia. Blood 100:1590-1595, 2002.
112. DeAngelo DJ, Hochberg EP, Alyea EP, et al: Extended follow-up of patients treated with imatinib mesylate (gleevec) for chronic myelogenous leukemia relapse after allogeneic transplantation: Durable cytogenetic remission and conversion to complete donor chimerism without graft-versus-host disease. Clin Cancer Res 10:5065-5071, 2004.
113. Hess G, Bunjes D, Siegert W, et al: Sustained complete molecular remissions after treatment with imatinib-mesylate in patients with failure after allogeneic stem cell transplantation for chronic myelogenous leukemia: Results of a prospective phase II open-label multicenter study. J Clin Oncol 23:7583-7593, 2005.
114. Olavarria E, Ottmann OG, Deininger M, et al: Response to imatinib in patients who relapse after allogeneic stem cell transplantation for chronic myeloid leukemia. Leukemia 17:1707-1712, 2003.
115. Deininger M, Schleuning M, Greinix H, et al: The effect of prior exposure to imatinib on transplant-related mortality. Haematologica 91:452-459, 2006.
116. Pinilla-Ibarz J, Cathcart K, Scheinberg DA: CML vaccines as a paradigm of the specific immunotherapy of cancer. Blood Rev 14:111-120, 2000.
117. Quintas-Cardama A, Cortes J: Chronic myeloid leukemia: Diagnosis and treatment. Mayo Clin Proc 81:973-988, 2006.
118. Cathcart K, Pinilla-Ibarz J, Korontsvit T, et al: A multivalent bcr-abl fusion peptide vaccination trial in patients with chronic myeloid leukemia. Blood 103:1037-1042, 2004.
119. Bocchia M, Gentili S, Abruzzese E, et al: Effect of a p210 multipeptide vaccine associated with imatinib or interferon in patients with chronic myeloid leukaemia and persistent residual disease: A multicenter observational trial. Lancet 365:657-662, 2005.